AR121268A1 - Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante - Google Patents

Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante

Info

Publication number
AR121268A1
AR121268A1 ARP210100294A ARP210100294A AR121268A1 AR 121268 A1 AR121268 A1 AR 121268A1 AR P210100294 A ARP210100294 A AR P210100294A AR P210100294 A ARP210100294 A AR P210100294A AR 121268 A1 AR121268 A1 AR 121268A1
Authority
AR
Argentina
Prior art keywords
von willebrand
menorragia
patients
administration
treatment
Prior art date
Application number
ARP210100294A
Other languages
English (en)
Inventor
Bettina Ploder
Franoise Truong-Berthoz
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR121268A1 publication Critical patent/AR121268A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente se refiere a un método para tratar la menorragia en un sujeto con la enfermedad de von Willebrand (VWD) que comprende la administración al sujeto de una cantidad terapéutica de un factor de von Willebrand (rVWF).
ARP210100294A 2020-02-04 2021-02-04 Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante AR121268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062969998P 2020-02-04 2020-02-04

Publications (1)

Publication Number Publication Date
AR121268A1 true AR121268A1 (es) 2022-05-04

Family

ID=74759563

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100294A AR121268A1 (es) 2020-02-04 2021-02-04 Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante

Country Status (12)

Country Link
US (1) US20230398188A1 (es)
EP (1) EP4100048A1 (es)
JP (1) JP2023514541A (es)
KR (1) KR20220150303A (es)
CN (1) CN115335074A (es)
AR (1) AR121268A1 (es)
AU (1) AU2021216945A1 (es)
BR (1) BR112022015326A2 (es)
CA (1) CA3169996A1 (es)
MX (1) MX2022009492A (es)
TW (1) TW202134266A (es)
WO (1) WO2021158777A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
BRPI0919693A2 (pt) 2008-10-21 2020-08-11 Baxter Healthcare S.A formulação farmacêutica estável liofilizada
CN103097522A (zh) 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组adamts13的方法
DK3412305T3 (da) 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf

Also Published As

Publication number Publication date
AU2021216945A1 (en) 2022-09-01
WO2021158777A1 (en) 2021-08-12
KR20220150303A (ko) 2022-11-10
MX2022009492A (es) 2022-11-09
BR112022015326A2 (pt) 2022-10-11
TW202134266A (zh) 2021-09-16
CA3169996A1 (en) 2021-08-12
EP4100048A1 (en) 2022-12-14
US20230398188A1 (en) 2023-12-14
JP2023514541A (ja) 2023-04-06
CN115335074A (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
AR047779A1 (es) Composiciones y metodos para tratar diabetes
EA201400394A1 (ru) Терапия глатирамером ацетатом с низкой кратностью
RU2013123646A (ru) Комбинированная композиция
PE20221338A1 (es) Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
CO2021006290A2 (es) Dosificación subcutánea y administración de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh)
Ozgul et al. Effect of alkalinisation of lignocaine for propofol injection pain: a prospective, randomised, double-blind study
AR121268A1 (es) Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
RU2009101026A (ru) Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
CO2020001322A2 (es) Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
Saha et al. Effectiveness and safety of autologous platelet-rich plasma therapy with total contact casting versus total contact casting alone in treatment of trophic ulcer in leprosy: An observer-blind, randomized controlled trial
CO2021011340A2 (es) Métodos de tratamiento profiláctico con vwf recombinante (rvwf)
RU2423118C1 (ru) Способ лечения трофических язв
CO2020001314A2 (es) Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante
RU2710541C1 (ru) Способ лечения ангулярного хейлита, возникшего вследствие дефицита рибофлавина
BR112017022478A2 (pt) composição farmacêutica de liberação sustentada que contém rivastigmina
Ates et al. Effect of paracetamol pretreatment on rocuronium induced injection pain: a randomized, double-blind, placebo-controlled comparison with lidocaine
RU2585097C1 (ru) Способ лечения хронического панкреатита
Yutskovskaya et al. Neck and chest: MesoCaHA for cheeks, neck, and décolletage
YUTSKOVSKAYA et al. Neck and chest
US10835553B2 (en) Application of hydroxypropyl methyl cellulose in preparation of medicine for treatment of esophageal mucosa
Yadav et al. Comparison of dexmedetomidine and dexamethasone as an adjuvant to bupivacaine in supraclavicular block
RU2295349C2 (ru) Способ лечения остеоартроза коленных суставов с использованием внутрисуставного введения препарата "хондролон"